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Abstract
Due to the intrinsic resistance of Burkholderia cepacia complex (Bcc) to many antibiotics and the production of a broad
range of virulence factors, lung infections by these bacteria, primarily occurring in cystic fibrosis (CF) patients, are very
difficult to treat. In addition, the ability of Bcc organisms to form biofilms contributes to their persistence in the CF lung. As
Bcc infections are associated with poor clinical outcome, there is an urgent need for new effective therapies to treat these
infections. In the present study, we investigated whether liposomal tobramycin displayed an increased anti-biofilm effect
against Bcc bacteria compared to free tobramycin. Single particle tracking (SPT) was used to study the transport of
positively and negatively charged nanospheres in Bcc biofilms as a model for the transport of liposomes. Negatively
charged nanospheres became immobilized in close proximity of biofilm cell clusters, while positively charged nanospheres
interacted with fiber-like structures, probably eDNA. Based on these data, encapsulation of tobramycin in negatively
charged liposomes appeared promising for targeted drug delivery. However, the anti-biofilm effect of tobramycin
encapsulated into neutral or anionic liposomes did not increase compared to that of free tobramycin. Probably, the fusion
of the anionic liposomes with the negatively charged bacterial surface of Bcc bacteria was limited by electrostatic repulsive
forces. The lack of a substantial anti-biofilm effect of tobramycin encapsulated in neutral liposomes could be further
investigated by increasing the liposomal tobramycin concentration. However, this was hampered by the low encapsulation
efficiency of tobramycin in these liposomes.
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Introduction
Cystic fibrosis (CF) is the most prevalent hereditary disease in
the Caucasian population and is caused by mutations in both cftr
alleles encoding a chloride channel [1]. The absence of a
functional chloride channel (CFTR channel) results in the
secretion of thick, viscous mucus in several organs, including the
lungs and the gastrointestinal tract [2]. The presence of thick
mucus in the lungs impairs the mucociliary clearance, rendering
CF patients more susceptible to lung infections. These lung
infections are not sufficiently cleared and rapidly evolve in chronic
infections, the main cause of morbidity and mortality in CF
patients [3]. The most significant pathogen colonizing the CF
lungs is Pseudomonas aeruginosa. Over time, approximately 80% of
the CF population becomes infected with this pathogen [4].
Compared to P. aeruginosa, Burkholderia cepacia complex (Bcc)
infections only account for a small percentage of the respiratory
infections within the CF population. However, they are often
associated with rapid deterioration of the lung function and
increased mortality [5]. The capacity of Bcc species to cause
invasive disease and their high level of intrinsic antibiotic
resistance make them particularly difficult to eradicate. Through
the production of different exopolymeric substances (EPS)
additional protection is provided against antibiotics and host
immune components [6]. As there is still no optimal treatment
regimen for Bcc infections in CF patients [7], these pathogens
continue to be highly problematic [8] emphasizing the urgent need
for effective antibiotic therapies. As for P. aeruginosa, the production
of EPS by Bcc strains is essential for the formation of thick and
mature biofilms [9]. These EPS, including polysaccharides and
extracellular DNA (eDNA), can delay the penetration of an
antibiotic through the biofilm [10]. By the encapsulation of the
antibiotic in a liposomal carrier, interactions between the
antibiotic and EPS could be avoided, resulting in an improved
anti-biofilm effect. In addition, liposome-encapsulated antibiotics
are protected from degradation by antibiotic-inactivating enzymes
(like b-lactamases) which can accumulate in the biofilm matrix
[11]. Another important factor contributing to antibiotic resistance
in several Gram-negative bacteria, including P. aeruginosa and Bcc
species, is their low outer membrane permeability [12–14]. The
uptake of antibiotics encapsulated in neutral liposomes is not
affected by this outer membrane barrier as this can occur through
direct fusion of the liposome with the bacterial membrane [15]. It
has been shown that subinhibitory concentrations of tobramycin
encapsulated in neutral liposomes displays a high bactericidal
activity against planktonic cultures of several bacterial species,
including P. aeruginosa and B. cenocepacia [16–18], probably due to
an enhanced uptake of the antibiotic. Besides the improved
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transport through the biofilm and a better uptake in the cell,
liposomes could provide selective delivery to the target site by
incorporating specific ligands to the liposome surface. Currently,
several liposome based drugs have been approved for clinical use
and various others are in clinical trials [19]. Arikace, a neutral
liposomal amikacin formulation, currently undergoes phase III
clinical trials for the treatment of lung infections [19,20]. It is the
first liposomal drug being investigated for aerosol delivery.
In the present study, we investigated whether the bactericidal
effect of tobramycin against Bcc biofilms could be increased by
encapsulating the antibiotic in liposomes. Therefore, we analyzed
the behavior of positively and negatively charged nanoparticles in
Bcc biofilms by means of single particle tracking (SPT) as a model
for liposomal transport. According to our observations, negatively
charged particles were directed towards cell clusters, while
positively charged particles became immobilized by interactions
with fiber-like structures (likely eDNA) in the biofilm matrix. Based
on these results, tobramycin encapsulated in anionic liposomes
could be promising in terms of targeted drug delivery. We
consequently evaluated the activity of neutral (reference) and
anionic liposomal tobramycin formulations against Bcc biofilms.
Materials and Methods
Strains
We used 5 Bcc strains in the present study: B. cenocepacia LMG
16656 and LMG 18829, B. cepacia LMG 1222, B. multivorans LMG
18825 and B. dolosa LMG 18943. All Bcc strains were obtained
from the BCCM/LMG Bacteria Collection (Ghent, Belgium) or
were kindly provided by Dr. P. Vandamme (Ghent University,
Belgium). The bacteria were stored in Microbank tubes (Prolab
Diagnostics, Richmond Hill, ON, Canada) at 280uC and
transferred twice on Mueller Hinton (MH) (Lab M, Heywood,
UK) agar plates before use in any experiment.
Lipids
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cho-
lesterol were obtained from Sigma-Aldrich (St. Louis, MO, USA)
and stored at 220uC. 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol sodi-
um salt (DPPG), were obtained from Corden Pharma Interna-
tional (Plankstadt, Germany) and stored at 220uC. Lipids were
dissolved in chloroform and stock solutions were stored between
2–8uC.
Nanoparticles
Yellow-green (lex:505/lem:515) fluorescent carboxylate-modi-
fied polystyrene FluoSpheres of 0.2 mm diameter were purchased
from Invitrogen (Carlsbad, CA, USA). Positively charged nano-
spheres were prepared from the carboxylate-modified FluoSpheres
by modification with N,N-dimethylethylenediamine (DMEDA)
(Sigma-Aldrich) as described previously [21]. The size and zeta-
potential of the positively charged nanospheres were measured in
HEPES (pH 7.3, 20 mM) using the Zetasizer Nano-ZS (Malvern,
Worcestershire, UK).
Single Particle Tracking Setup
All SPT measurements were performed on a custom-built laser
wide-field fluorescence microscope setup as described previously
[22]. Briefly, two solid-state lasers, a 100 mW Calypso 491 nm
(Cobolt, Solna, Sweden) and a 100 mW Spectra Physics Excelsior
642 nm (CA, USA), were used to excite the fluorophores in
samples mounted on a TE2000-E (Nikon BeLux, Brussels,
Belgium) inverted microscope equipped with a Plan Apo VC
10061.4 NA oil immersion objective lens (Nikon). A diffuser in the
illumination path ensured even illumination of the sample. An
acousto-optical tunable filter (AOTF) was used to modulate the
intensity of the laser beams. The AOTF was synchronized to the
EMCCD camera (Cascade II:512; Roper Scientific, Tucson, AZ,
USA) in order to limit photobleaching during imaging. Videos of
the moving nanoparticles were acquired with the NIS Elements
software package (Nikon).
Analysis of SPT Data
Analysis of the videos was performed off-line using software
developed by Braeckmans et al. [23]. First, the particles were
localized in all frames of the SPT movie. A selection of ‘‘real’’
particles was made according to user-defined criteria, including
size, contrast relative to the local background and sphericity.
Subsequently, individual trajectories of the nanospheres were
calculated using a nearest neighbor algorithm. The positions of
nanospheres that are closest to each other were connected in
subsequent image frames, taking into consideration the maximum
distance a particle can reasonably move from one frame to
another. The trajectories were further analyzed based on mean
square displacement (MSD) analysis. The MSD was calculated for
every available time lag (t), i.e. the multiples of time between two
subsequent images in an SPT movie.
A weighted least squares fitting was performed of
MSD~Ctaz4s2
to theMSD vs. t curves, yielding for each trajectory the parameters
Gamma (C), alpha (a) and sigma (s). Gamma is the so-called
transport coefficient, alpha the anomalous exponent and sigma a
parameter taking into account the limited precision with which a
particle can be localized. The parameter of interest was alpha,
which contains information on the mode of motion. For free
diffusion, a equals 1 while a ,1 and a .1 represent sub- and
super-diffusion, respectively. By analyzing the MSD versus t plots
of many trajectories, a distribution of a values was obtained. In
addition, the apparent diffusion coefficient, Da, was calculated
corresponding to the first time lag according to:
Da~MSD= 4tð Þ
The distribution of Da values was further processed using a
maximum entropy method (MEM) which improves the resolution
and at the same time smoothes the curve by only retaining the
features that are statistically warranted by the data [22].
SPT Measurements in Biofilms
Bcc biofilms were cultured in uncoated 35 mm glass bottom
culture dishes (MatTek, Ashland, MA, USA). The dishes were
inoculated with 2 mL of a standardized bacterial suspension (,108
CFU/mL in MH broth) in the presence or absence of 10 mg/mL
dornase alfa (Pulmozyme, Genentech, SF, USA) and were
incubated at 37uC. After 4 h, the supernatant, containing non-
adhered cells, was removed and adhered cells were carefully
washed with physiological saline (0.9% w/v NaCl) (PS). Subse-
quently, 2 mL of fresh MH broth (with or without 10 mg/mL
dornase alfa) was added and the dishes were incubated for another
20 h at 37uC. After 24 h of biofilm formation, the supernatant was
removed and biofilms were gently washed with PS. Biofilm cells
were stained by adding 1 mL of a Syto 59 (Invitrogen) solution
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(5 mM in PS). After 15 min of incubation at room temperature,
protected from light, the biofilm was washed twice with PS. The
nanoparticle stock suspensions were sonicated for 10 min before
dilution in PS (,0.002% solids). One mL of this particle
suspension was added to the biofilms, right before recording
movies. Movies of 5 s with a temporal resolution of 39.2 ms (time
between two subsequent images, time lag) and an image
acquisition time of 3 ms were recorded. Dual color image
acquisition allowed easy navigation within the biofilm. Between
25 and 30 movies on different locations in the biofilm were
recorded. Each experiment was carried out in triplicate at room
temperature.
Liposome Preparation
Liposomes were prepared by a dehydration-rehydration method
as described previously [24]. In brief, for the preparation of
neutral liposomes, 50 mmol of DPPC and 25 mmol of cholesterol
were dissolved in 1 mL of chloroform in a round-bottomed flask.
For the anionic liposomes, 53 mmol of DOPC and 6.6 mmol of
DPPG were dissolved in 1 mL of chloroform. The round-
bottomed flask was connected to a rotary evaporator to dry the
lipid film under controlled vacuum at 50uC. The lipid film was
rehydrated with 2 mL of a sucrose solution in distilled water (1:1,
w/w, sucrose to lipid). Sucrose is needed to stabilize the liposomes
during freeze drying. Lipid suspensions were vortexed to form
multilamellar vesicles and then sonicated for 5 min in an
ultrasonic bath (Branson 3510), followed by two additional cycles
of vortexing and sonication. The resulting suspension was then
mixed with 1 mL (40 mg/mL) of tobramycin in PS. The mixture
was frozen (220uC) and immediately freeze dried. After freeze
drying, the powdered formulations were stored at 4uC until use.
For rehydration, 200 mL of distilled water at 50uC was added. The
suspension was vortexed and incubated for 30 min at 50uC. These
steps were repeated with 200 mL phosphate-buffered saline (PBS,
pH 5.9). After incubation at 50uC, 1.6 mL of PBS was added, the
mixture was vortexed and incubated for another 30 min at 50uC.
Non-encapsulated tobramycin was removed following three
rounds of PBS wash (183006g, 15 min at 4uC) and the pellet
was resuspended in 2 mL PS. The size and zeta-potential of the
liposomes were measured in HEPES (pH 7.3, 20 mM) using the
Zetasizer Nano-ZS (Malvern, Worcestershire, UK).
Quantification of the Amount of Encapsulated
Tobramycin
The concentration of liposome encapsulated tobramycin was
measured by agar diffusion, using a laboratory strain of Bacillus
subtilis (ATCC 6633) as indicator organism. B. subtilis ATCC 6633
spore suspensions were prepared as described in the European
Pharmacopoeia [25]. In brief, B. subtilis was grown at 35–37uC for
7 days on Antibiotic medium 1 (AM1) supplemented with
0.001 g/L manganese sulphate. After at least 7 days, the growth,
which mainly consisted of spores, was washed off using sterile
water. The obtained suspension was heated at 70uC for 30 min
and diluted to give an appropriate concentration of spores (107–
108 per mL). The spore suspensions were stored at 4uC until use.
We used this suspension to prepare a 1% suspension of spores
(4 mL/400 mL) in warm (47.5uC) AM 11 agar. The agar was
poured into a sterile glass plate and was left to solidify for 15 min
at room temperature. To lyse the liposomes, 0.2% Triton X-100
was added to the liposomal solutions. This level of Triton X-100
had no effect on the performance of the assay (data not shown).
Wells of 5 mm diameter were punched in the agar and filled with
200 mL of standard tobramycin solutions or with the sample. The
plate was covered with a steel lid and incubated for 20 hours at
35uC after 4 h of pre-diffusion at 4uC. We subsequently measured
the inhibition zones and the average of 4 measurements was used
for data analysis. A standard curve of known concentrations of free
tobramycin (0.03125–1 mg/mL) was constructed and was utilized
to calculate the amount of encapsulated tobramycin that was
released after Triton X-100 treatment.
Determination of the MIC of Tobramycin
MICs were determined in duplicate according to the EUCAST
broth microdilution protocol using unsupplemented MH broth. In
brief, bacterial suspensions were standardized at ,56105 CFU/
mL before inoculation of a flat-bottomed 96-well plate filled with
100 mL of tobramycin serial dilutions in MH. The range of
tobramycin concentrations used was from 2 to 1024 mg/L. Plates
were incubated at 37uC for 20 h and the optical density was
determined at 590 nm using a multilabel microtitre plate reader
(Envision, Perkin Elmer LAS, Waltham, MA, USA). The MIC is
the lowest antibiotic concentration for which a similar optical
density was observed in the inoculated and blank wells.
Activity of Liposome Encapsulated Tobramycin Against
Bcc Biofilms
Biofilms were cultured in round-bottomed 96-well plates. An
inoculum was prepared by suspending bacteria from a pure
culture on MH agar in MH broth. The inoculum was
standardized at ,108 CFU/mL and the wells of the microtitre
plate were filled with 100 mL of this suspension. Plates were
incubated at 37uC without shaking. After 4 h, the supernatant,
containing planktonic cells, was aspirated from the wells. Adhered
cells were carefully washed with 100 mL of PS and 100 mL of fresh
sterile MH broth was added. Plates were incubated for an
additional 20 h at 37uC. After 24 h of biofilm formation, biofilms
were washed with 100 mL of PS before treatment with free
tobramycin (final concentrations of 140 mg/mL or 4XMIC of
tobramycin in PS) or liposome encapsulated tobramycin (final
concentrations of 140 mg/mL or 4XMIC of tobramycin in PS).
After 24 h of treatment at 37uC, cell numbers were determined by
plate counting.
Results
Properties of Nanoparticles and Liposomes
The average sizes and average zeta-potentials of nanospheres
and liposomes used in the present study are shown in Table 1. For
the liposomes, the concentrations of encapsulated tobramycin (i.e.
the concentration that is released after breaking up all liposomes in
the solution with Triton X-100) are also shown in Table 1.
Transport of Negatively Charged Nanoparticles in Bcc
Biofilms
The mobility of carboxylate-modified polystyrene nanospheres
(0.2 mm) added to Bcc biofilms was studied by analyzing individual
trajectories of the nanospheres in the biofilm. The distribution of a
values and Da coefficients of the carboxylate-modified nanospheres
is shown in Figure 1. Average a and Da values for all conditions are
shown in Table 2. For all strains investigated, negatively charged
particles display subdiffusion (0,a,1 ) when added to the biofilm.
This most pronounced subdiffusion is observed in B. cenocepacia
LMG 16656 and B. cenocepacia LMG 18829 biofilms and to a lesser
extent in B. multivorans LMG 18825 and B. cepacia LMG 1222
biofilms. This is also reflected in the Da distributions where an
immobilized fraction is observed in both B. cenocepacia LMG 16656
and B. cenocepacia LMG 18829 biofilms. This anomalous diffusion
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indicates that the negatively charged particles strongly interact
with the biofilms. In addition, the particles diffuse slowly in the
biofilm as their apparent diffusion coefficients are much lower
than those in water (Dw=1.96 mm2/s (26)). The highest diffusion
rates were observed in a B. cepacia LMG 1222 biofilm (average
Da=0.42 mm2/s) while the lowest were observed in a B. multivorans
LMG 18825 biofilm (average Da=0.15 mm2/s). The mobility of
the negatively charged nanospheres in both B. cenocepacia LMG
16656 and LMG 18829 biofilms is similar, yielding average
diffusion coefficients of 0.26 and 0.28, respectively.
Transport of Positively Charged Nanoparticles in Bcc
Biofilms
The mobility of DMEDA-modified polystyrene nanospheres
(0.2 mm) in different Bcc biofilms was also studied (Figure 2).
Positively charged nanospheres displayed subdiffusion in all Bcc
biofilms grown in the absence of dornase alfa. Alfa values for B.
cepacia LMG 1222 show a bimodal distribution, with part of the
particles displaying free diffusion. Anomalous subdiffusion was
most pronounced in B. cenocepacia LMG 18829 (mean a=0.23). In
contrast, a values closest to 1 were obtained in B. multivorans LMG
18825 and B. cepacia LMG 1222 biofilms, with mean a values of
0.65 and 0.62, respectively. This correlates with the highest
Table 1. Characteristics of the nanospheres and liposomes used in the present study (n = 3).
Particle
Average size
(nm) (6SD)
Average zeta-potential
(mV) (6SD)
Total lipsomal tobramycin concentration
(mg/mL) (6SD)
Carboxylate-modified nanosphere 224.0 (60.7) 248.4 (60.7) /
DMEDA-modified nanosphere 231.9 (61.2) 30.4 (60.6) /
DPPC/cholesterol liposomes
(2/1, molar ratio)
426.3 (626.4) 20.5 (60.1) 141 (635)
DOPC/DPPG liposomes
(8/1, molar ratio)
228.5 (634.9) 222.3 (60.5) 1128(616)
doi:10.1371/journal.pone.0079220.t001
Figure 1. Mobility of 0.2 mm carboxylate-modified nanospheres in Bcc biofilms.
doi:10.1371/journal.pone.0079220.g001
Transport in Bcc Biofilms
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e79220
average apparent diffusion coefficient (average Da=0.44) in B.
multivorans LMG 18825 biofilms. Although the average diffusion
coefficient in B. cepacia LMG 1222 is much smaller, the distribution
is clearly bimodal, with two groups of particles behaving
differently. The peak of the faster moving population represents
particles with an apparent diffusion coefficient of 0.41 mm2/s. Still,
positively charged nanospheres diffuse much more slowly in the
Bcc biofilms than in water (Dw=1.88 mm2/s [26]). The hindered
transport of positively charged particles in Bcc biofilms could be
due to interaction with negatively charged matrix components. It
was previously observed that cationic nanospheres interacted with
fiber-like structures in Bcc biofilms, greatly impairing their
mobility and this was confirmed in the present study (Movie S1
and Movie S2). As these fiber-like structures are likely eDNA, the
experiments with DMEDA-modified nanospheres were repeated
in biofilms grown in the presence of dornase alfa (10 mg/mL)
(Figure 2). The most pronounced effect of dornase alfa on the
mobility of positively charged nanospheres was observed in B.
cepacia LMG 1222 and B. cenocepacia LMG 18829 biofilms for
which average diffusion coefficients approximately doubled, from
0.27 to 0.45 mm2/s and from 0.23 to 0.54 mm2/s, respectively. In
addition the a distributions of the positively charged nanospheres
displayed a shift to higher values, although this shift was less
pronounced in B. cenocepacia LMG 16656 and B. multivorans LMG
18825 (Figure 2).
Activity of Liposome Encapsulated Tobramycin Against
Bcc Biofilms
We tested the activity of both neutral and negatively charged
liposomes containing tobramycin against Bcc biofilms (Figure 3).
When added at a final concentration of 140 mg/mL (Figure 3a),
free tobramycin showed modest activity against B. cenocepacia LMG
18829, B. multivorans LMG 18825 and B. dolosa LMG 18943 and
strong activity against B. cepacia LMG 1222. This is in agreement
with the MIC values observed. The MIC for B. cepacia LMG 1222
is low (32 mg/mL) while these for B. cenocepacia LMG 18829, B.
multivorans LMG 18825 and B. dolosa LMG 18943 were only
slightly below (128 mg/mL) the tobramycin concentration tested
(140 mg/mL). Finally, the MIC of tobramycin for B. cenocepacia
LMG 16656 (256 mg/mL) is considerably above the concentration
used in this experiment, explaining the lack of bactericidal activity
(Figure 3A). Both neutral and negatively charged liposomes
containing 140 mg/mL of tobramycin (< 4XMIC) showed a
bactericidal effect against B. cepacia LMG 1222 biofilms but no
increased bactericidal activity compared to free tobramycin was
observed. In B. multivorans LMG 18825 biofilms, neutral liposomes
containing 140 mg/mL tobramycin (< MIC) showed the same
activity as free tobramycin. Previous research from our group has
indicated that tobramycin at concentrations of 4XMIC yielded a
substantial bactericidal effect against Bcc biofilms [27]. Increasing
the liposomal tobramycin concentration to 4XMIC was only
possible for the negatively charged liposomes as the maximum
achievable concentration of encapsulated tobramycin in neutral
liposomes was 140 mg/mL. However, at this increased tobramycin
concentration, negatively charged liposomal tobramycin formula-
tions only showed bactericidal activity against B. cepacia LMG
1222 (Figure 3B).
Discussion
In the present study we investigated the transport of negatively
and positively charged nanospheres in Bcc biofilms. The transport
of nanospheres can be used as a model to predict the transport of
antibiotic-containing liposomes. Liposomes are made up of
phospholipids and can act as biodegradable delivery systems.
Antibiotics encapsulated in liposomes have lower toxicity and
higher bioactivity and bioavailability [18,28]. It has already been
demonstrated that liposomal antibiotic formulations show in-
creased bactericidal activity against biofilms compared to free
antibiotics [29,30]. However, a first condition is that efficient
transport of liposomes in the biofilm matrix takes place. Therefore,
as a first step in developing a drug-delivery system with activity
against Bcc biofilms, we studied the transport of model
nanospheres in these biofilms. In a previous study we have shown
that PEGylated neutral nanospheres displayed normal (unob-
structed) diffusion in B. multivorans LMG 18825 biofilms and that
Table 2. Average apparent diffusion coefficients, both in Bcc biofilms and in water [26], and average a values of the nanospheres
in Bcc biofilms.
Biofilm Condition Particle Av Da (mm2/s) (6SD) Av a Av Dw (mm2/s) (6SD)
B. cenocepacia LMG 16656 Control Carboxylate-modified 0.26 (60.29) 0.43 1.96 (60.02)
Control DMEDA-modified 0.29 (60.21) 0.39 1.88 (60.09)
Dornase a DMEDA-modified 0.37 (60.44) 0.44
B. cenocepacia LMG 18829 Control Carboxylate-modified 0.28 (60.36) 0.48 1.96 (60.02)
Control DMEDA-modified 0.23 (60.30) 0.23 1.88 (60.09)
Dornase a DMEDA-modified 0.54 (60.30) 0.49
B. cepacia LMG 1222 Control Carboxylate-modified 0.42 (60.25) 0.81 1.96 (60.02)
Control DMEDA-modified 0.27 (60.28) 0.62 1.88 (60.09)
Dornase a DMEDA-modified 0.45 (60.26) 0.97
B. multivorans LMG 18825 Control Carboxylate-modified 0.15 (60.11) 0.77 1.96 (60.02)
Control DMEDA-modified 0.38 (60.20) 0.65 1.88 (60.09)
Dornase a DMEDA-modified 0.42 (60.30) 0.67
B. dolosa LMG 18943 Control Carboxylate-modified 0.32 (60.36) 0.57 1.96 (60.02)
Control DMEDA-modified 0.25 (60.30) 0.35 1.88 (60.09)
Dornase a DMEDA-modified 0.19 (60.30) 0.53
doi:10.1371/journal.pone.0079220.t002
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these particles diffuse in the biofilm at similar rates as in water
[26]. This was in contrast to the mobility of carboxylate- and
DMEDA-modified nanopsheres in a B. multivorans LMG 18825
biofilm which was found to be strongly impeded [26]. In the
present work we expanded the panel of Bcc strains to study the
diffusion in biofilms of both carboxylate- and DMEDA-modified
nanospheres. The negatively charged nanospheres moved 5 to 13
times more slowly in all Bcc biofilms tested compared to in water.
In all biofilms, a fraction of relatively immobile negatively charged
particles, characterized by Da values close to zero, was observed.
This immobilization is probably caused by electrostatic interac-
tions between positively charged components of the biofilm and
the negatively charged nanospheres, which correlates with the
average a ,1 values observed for these particles, indicating
anomalous subdiffusion. It was previously observed that positively
charged particles are immobilized on fiber-like structures, which
were hypothesized to be eDNA [26]. Here we investigated this
further by studying the transport of DMEDA-modified nano-
spheres in biofilms grown in the presence of dornase alfa. In
general it was found that dornase alfa treatment reduced the
extent of anomalous diffusion and improved the diffusion rate,
supporting the view that positively charged particles can get
trapped by binding to eDNA in the biofilm matrix. As DMEDA-
modified nanospheres interact with eDNA, the application of
positively charged liposomes as antibiotic carrier systems can only
be considered in combination with e.g. dornase alfa. However, as
previous research has indicated that the use of dornase alfa could
be contraindicated in CF patients infected with B. cenocepacia [31],
we did not test the effect of tobramycin encapsulated in positively
charged liposomes. Instead, the effect of tobramycin encapsulated
in negatively charged liposomes was compared to that of
tobramycin encapsulated in neutral liposomes. Neutral liposomal
formulations were tested as a reference as these appear, at first
sight, less interesting to treat Bcc biofilm infections based on the
mobility of neutral nanospheres which showed no enrichment in
B. multivorans LMG 18825 biofilms. In contrast, enrichement of
carboxylate-modified nanospheres at sites close to the bacteria has
been observed [26]. Therefore, if anionic liposomes behave
similarly in Bcc biofilms as anionic nanospheres, tobramycin
could potentially be targeted near the cell clusters when
encapsulated in anionic liposomes, resulting in an increased anti-
biofilm effect. At free tobramycin concentrations equal to 4XMIC,
a substantial bactericidal effect against all Bcc biofilms was
observed. Unfortunately, this anti-biofilm effect could not be
increased by encapsulating tobramycin in either neutral or anionic
liposomes. As the surface of Bcc cells is negatively charged it could
be that the fusion of anionic liposomes with the bacterial cells is
limited by repulsive forces at close proximity. The bactericidal
activity of tobramycin encapsulated in neutral liposomes at
concentrations of 4XMIC could only be tested against B. cepacia
LMG 1222 as this strain showed the lowest MIC (32 mg/mL) and
not more than 140 mg/mL of tobramycin could be encapsulated
in these neutral liposomes. The neutral liposomal tobramycin
formulation did not show an increased bactericidal effect
Figure 2. Mobility of 0.2 mm DMEDA- modified nanospheres in Bcc biofilms.
doi:10.1371/journal.pone.0079220.g002
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compared to that of free tobramycin. Although the observed
relatively unobstructed motion of neutral particles in B. multivorans
LMG 18825 biofilms suggests no penetration difficulties for
neutral liposomes in the biofilm, we did not observe a substantial
anti-biofilm effect. However, the effect of the neutral liposomal
tobramycin at a concentration of 140 mg/mL was not decreased
compared to the effect of free tobramycin in B. multivorans LMG
18825 biofilms, indicating that the encapsulated tobramycin does
enter the cell. Possible explanations for the lack of an anti-biofilm
effect of neutral formulations of liposomal tobramycin in B.
cenocepacia LMG 16656, B. cenocepacia LMG 18829 and B. dolosa
LMG 18943 are that a hydrophilic EPS layer in close proximity to
the biofilm cells protects them from fusion with the liposomal
carrier system. Alternatively, it could be that the transport of
nanospheres is not a good model for the transport of liposomes in
Bcc biofilms, especially for the neutral liposomes which are twice
the size of the nanospheres. Smaller sized neutral liposomes with
equal tobramycin encapsulation efficiency would allow to inves-
tigate this further but the low encapsulation efficiency of
tobramycin into neutral liposomes [24] makes this impossible at
present.
Conclusions
Both positively- and negatively charged nanospheres show slow
subdiffusion in Bcc biofilms. While positively charged nanospheres
likely interact with eDNA, negatively charged nanospheres
probably bind to positively charged matrix components. As
previous research from a collaborating research group has
indicated an enrichment of negatively charged nanospheres close
Figure 3. Activity of free and liposomal tobramycin against Bcc biofilms.
doi:10.1371/journal.pone.0079220.g003
Transport in Bcc Biofilms
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e79220
to biofilm clusters, anionic liposomes could possibly serve as
antibiotic delivery systems with high potential for treatment of Bcc
biofilm infections. However, anionic liposomal formulations with
tobramycin concentrations of 4XMIC only displayed bactericidal
activity against B. cepacia LMG 1222 biofilms. In contrast, free
tobramycin at this concentration showed high bactericidal activity
against all Bcc biofilms tested. The fusion of the negatively charged
liposome with the negatively charged bacterial membrane is likely
limited by electrostatic repulsive forces at close proximity.
Although we observed unobstructed diffusion of neutral nano-
spheres, the use of a neutral liposomal tobramycin formulation did
not result in an increased anti-biofilm effect compared to free
tobramycin. Additional research for the development of an
optimal tobramycin carrier to treat Bcc biofilm infections is
needed.
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